Contribute Try STAT+ Today

WASHINGTON — It’s the eve of a major speech by the president, and it’s anyone’s guess what he will say about drug pricing. Swirling rumors have roiled the pharmaceutical industry and Congress over the past week. Top leaders in Congress have no idea what the White House actually supports. Sound familiar?

Democratic leaders in the White House and Congress clearly aren’t on the same page, a division reminiscent of the yearslong infighting over drug pricing policy under Republican leadership in Washington — an infighting Democrats often criticized. It’s a noticeable contrast from the trillions of dollars worth of domestic policy President Biden’s team has released in his first 100 days in office, which has come out with remarkable discipline and near-uniform support from the rest of the party.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.